Home » Blog » Company News

Company News

  • How the SLE Model Shapes Future Lupus Treatments

    2024-11-05

    Lupus, particularly Systemic Lupus Erythematosus (SLE), is a complex autoimmune condition. It demands a multifaceted approach to both research and treatment. The SLE model, a cornerstone in this domain, is pivotal for understanding the intricacies of lupus and developing effective therapies. In thi Read More
  • Insights into dsDNA's Role in SLE Model Studies

    2024-10-29

    Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by the production of autoantibodies and widespread inflammation. One of the pivotal components implicated in the pathogenesis of SLE is double-stranded DNA (dsDNA). Understanding the role of dsDNA in SLE model studies i Read More
  • What is PSO Model?

    2024-08-22

    The Pso (Psoriasis) model is a critical tool in the field of dermatological research, particularly for understanding and developing treatments for Psoriasis. Psoriasis is a chronic autoimmune skin disease characterized by red, itchy, and scaly patches. The Pso model, which includes various animal mo Read More
  • Understanding MC903 Induced AD Model in Detail

    2024-08-21

    Understanding MC903 Induced AD Model in DetailAtopic dermatitis (AD) is a chronic inflammatory skin condition characterized by erythematous plaques, eruptions, elevated serum IgE levels, and a T helper cell type 2 (Th2) cytokine profile, including interleukin-4 (IL-4) and interleukin-13 (IL-13). Mic Read More
  • What is an SLE Model?

    2024-08-19

    Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that affects multiple organ systems in the body. It is characterized by the production of autoantibodies and the formation of immune complexes, which subsequently lead to inflammation and damage to various tissues. The symptoms of SL Read More
  • What is the Function of AD Model?

    2024-08-17

    IntroductionAtopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by erythematous plaques, eruptions, and elevated serum IgE levels. It affects millions of people worldwide, causing significant discomfort and impacting the quality of life. The development of effective treatme Read More
  • How Are Animal Models Revolutionizing SLE Model Research?

    2024-08-15

    Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect virtually any organ system, leading to a wide range of symptoms and complications. Understanding this complex disease is a challenge that many researchers have faced over the years. The introduction of animal models i Read More
  • Company Headquarters Relocates to Suzhou Ascendas iHub Park

    2024-04-09

    Suzhou, China – April 8, 2023 –HKeybio, a leading industry player in Autoimmune disease models, is excited to announce the relocation of its headquarters to 2nd floor, Building B, Ascendas iHub Suzhou. The move comes as a result of the company's rapid expansion and growth.The new office space is des Read More
  • Celebrate Chinese New Year by Making Dumplings

    2024-04-09

    On February 8, 2024, colleagues at HKeybio Company came together to celebrate the Chinese New Year by making traditional dumplings. The festive atmosphere was filled with joy, laughter, and the delicious aroma of dumplings cooking in the kitchen.Employees from different departments gathered in the c Read More
  • Total 3 pages  Go to Page
  • Go
HKeybio is a Contract Research Organization (CRO) specializing in preclinical research within the field of autoimmune diseases.

Quick Links

Service Catagory

Contact Us

  Phone
Business Manager-Julie Lu:+86-18662276408
Business Inquiry-Will Yang:+86-17519413072
Technical Consultation-Evan Liu:+86-17826859169
us.bd@hkeybio.com; eu.bd@hkeybio.com; uk.bd@hkeybio.com.
  Add: Building B, No.388 Xingping Street, Ascendas iHub Suzhou Industrial Park, JIANGSU, CHINA
Leave a Message
CONTACT US
Sign up for our newsletter to receive the latest news.
​Copyright © 2024 HkeyBio. All rights reserved. | Sitemap | Privacy Policy